Human Oncology & Pathogenesis Program
The Ross Levine Lab
Research
The goal of our research is to improve our understanding of the genetic basis of blood disorders known as myeloid malignancies, and to use this knowledge to improve therapies for patients with these disorders. Our efforts are focused on the identification and characterization of somatic mutations in hematologic malignancies using candidate gene, genome-wide, and functional approaches, with a specific interest in the role of aberrant signal transduction in malignant transformation and in the effects of mutations in epigenetic modifiers in myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML). As a physician-scientist, we have a specific interest in translating this knowledge back to the clinic, in the preclinical and clinical evaluation of targeted therapies for leukemia patients, and in the development of clinically tractable genomic assays for patients with hematologic malignancies.
Featured News
Publications
People
Ross L. Levine, MD
- Mechanisms of genetic and epigenetic cooperativity which drive myeloid transformation; Elucidating and modeling evolution from hematopoietic stem/progenitor cells to clonal hematopoiesis and then to myeloid malignancies; Identification and credentialing novel therapeutic dependencies in myeloid malignancies
- MD, Johns Hopkins School of Medicine
- leviner@mskcc.org
- Email Address
- View physician profile
- Physician profile
Members
- BS, Universitat Autonoma de Barcelona
- MS, Fachhochschule Technikum Wien
- BA, University of Pennsylvania
- MS, University of Pennsylvania
- Drexel University
- University of Michigan
- 646-888-2796
- Lab Phone
- Rensselaer Polytechnic University
- 646-888-2796
- Lab Phone
- BS, Boston College
Lab Alumni
Lab Affiliations
Achievements
- Scholar, Leukemia and Lymphoma Society Scholar (2012)
- Louis and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2011)
- Member, American Society of Clinical Investigation (2011)
- Sir William Osler Young Investigator Award, Interurban Clinical Club (2011)
Get in Touch
-
Lab Head Email
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ross L. Levine discloses the following relationships and financial interests:
-
Ajax Therapeutics, Inc.
Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests; Provision of Services (uncompensated) -
Anovia Biosciences, Inc
Ownership / Equity Interests -
AstraZeneca
Provision of Services -
Auron Therapeutics, Inc.
Ownership / Equity Interests; Provision of Services (uncompensated) -
Bakx Therapeutics
Ownership / Equity Interests; Provision of Services (uncompensated) -
BridgeBio Inc.
Provision of Services -
C4 Therapeutics
Ownership / Equity Interests; Provision of Services -
Celgene
Provision of Services -
Cure Breast Cancer Foundation
Intellectual Property Rights -
ECOG-ACRIN Cancer Research Group
Provision of Services (uncompensated) -
Epiphanes, Inc.
Ownership / Equity Interests -
Epizyme
Intellectual Property Rights -
Genome Quebec
Provision of Services -
Gilead Pharmaceutical
Provision of Services -
Imago Biosciences
Ownership / Equity Interests; Provision of Services (uncompensated) -
Incyte
Provision of Services
-
Isoplexis Corporation
Ownership / Equity Interests -
Janssen Pharmaceuticals, Inc.
Provision of Services -
Jubilant Therapeutics Inc.
Provision of Services -
Kurome Therapeutics, Inc.
Ownership / Equity Interests -
Lilly Oncology
Provision of Services -
Mana Therapeutics, Inc.
Ownership / Equity Interests; Provision of Services -
Mission Bio
Ownership / Equity Interests; Provision of Services (uncompensated) -
Novartis Pharmaceuticals Corporation
Provision of Services -
PharmaEssentia
Provision of Services -
Prelude Therapeutics
Ownership / Equity Interests; Provision of Services -
Qiagen
Fiduciary Role/Position; Ownership / Equity Interests; Provision of Services (uncompensated) -
Scorpion Therapeutics, Inc.
Ownership / Equity Interests; Provision of Services -
Syndax
Ownership / Equity Interests; Provision of Services -
The Mark Foundation
Fiduciary Role/Position; Provision of Services -
University of Helsinki
Provision of Services -
Zentalis Pharmaceuticals
Ownership / Equity Interests; Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.